More drugs originate outside the industry than it claimsBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g1354 (Published 04 February 2014) Cite this as: BMJ 2014;348:g1354
- Jacqui Young
Many innovative drugs, especially to treat rare diseases, originate not from large drug companies but from small enterprises or academia, a new study has shown.
The research by the European Medicines Agency shows that 44% of innovative drugs recommended for marketing authorisation in the European Union originated from small or medium sized enterprises, academia, public bodies, and public-private partnerships.1
This seems to contradict the claim by Stephen Whitehead, chief executive of the Association of the British Pharmaceutical Industry, that the industry was responsible for developing 90% of the drugs available to patients. …
Log in using your username and password
Log in through your institution
Sign up for a free trial